Skip to main content

Table 3 Studies reporting CD112 as a diagnostic and prognostic biomarker

From: The CD112R/CD112 axis: a breakthrough in cancer immunotherapy

Reference

First Author

Year

Type of cancer

Sample size

comments

[68]

Miao et al.

2013

Gallbladder cancer

46 SC/ASCa

80 ACb

CD112 expression was associated with aggressiveness and poor prognosis

[44, 73]

Daniel et al.

Huang et al.

2021

2014

Liver cancer

159

Low CD112 expression was associated with poor OS of patients, but contradicted by evidence from preclinical studies

[80]

Karabulut et al.

2015

Colorectal carcinoma (CRC)

140

Serum CD112 levels have a diagnostic value and high levels correlated with an adverse prognostic impact on PFS patients with early-stage

[83]

Liang et al.

2015

Pancreatic Ductal Adenocarcinomas

106

CD112 expression was associated with the progression and poor prognosis

[84]

Izumi et al.

2015

Pancreatic adenocarcinoma

49

CD112 was not associated with overall survival, but higher CD112 expression correlated with worse histological grade.

[77]

Stamm et al.

2018

AML

429c

High CD112 expression correlated with shorter overall survival

[76]

Erturk et al.

2019

Lung cancer

74

Serum CD112 expression level was a reliable diagnostic but not prognostic or predictive biomarker.

[81]

Bekes et al.

2019

Ovarian cancer

60

CD112 expression supported tumor cell adhesion, leading to growth and lymph node metastasis.

  1. aSC/ASC: squamous cell/adenosquamous carcinoma
  2. b AC: adenocarcinomas
  3. cincluding 139 AML patients enrolled in the AMLSG 07–04 study of the German-Austrian Study Group (NCT00151242) [78] and 290 AML patients in the GEO database (GEO accession GSE6891) [79]